Cytovale, Inc.
Cytovale is dedicated to developing innovative diagnostic technologies that interrogate the innate immune response to improve patient care, particularly in the early detection and management of sepsis. The company aims to provide rapid, objective, and actionable diagnostic tools to enhance clinical decision-making and patient outcomes.
Industries
Nr. of Employees
small (1-50)
Cytovale, Inc.
2 Tower Place, 18th Floor, South San Francisco, CA 94080
Patents
Products
Immune-response based rapid sepsis diagnostic test
A rapid in vitro diagnostic assay that analyzes blood sample cellular biomechanics to produce a quantitative sepsis risk score and discrete risk bands for adult patients presenting to emergency departments; intended to support rapid triage and clinical decision-making.
Immune-response based rapid sepsis diagnostic test
A rapid in vitro diagnostic assay that analyzes blood sample cellular biomechanics to produce a quantitative sepsis risk score and discrete risk bands for adult patients presenting to emergency departments; intended to support rapid triage and clinical decision-making.
Services
Support for integrating rapid diagnostic risk scores into emergency department triage, Code Sepsis checklists, and existing clinical workflows to inform triage and treatment decisions.
Technical support channels for instrument operation, troubleshooting, and customer service for deployed diagnostic systems.
In-house verification and validation engineering to design tests, execute V&V plans, and document requirement coverage for device releases and cartridge iterations.
Support for integrating rapid diagnostic risk scores into emergency department triage, Code Sepsis checklists, and existing clinical workflows to inform triage and treatment decisions.
Technical support channels for instrument operation, troubleshooting, and customer service for deployed diagnostic systems.
In-house verification and validation engineering to design tests, execute V&V plans, and document requirement coverage for device releases and cartridge iterations.
Expertise Areas
- Rapid sepsis diagnostics for emergency departments
- Cellular biomechanical phenotyping
- Microfluidics-based assay development
- Clinical validation and regulatory clearance (FDA 510(k))
Key Technologies
- Deformability cytometry / cell mechanical phenotyping
- Microfluidics
- Cell imaging for phenotypic analysis
- Rapid in vitro diagnostic (IVD) assay platforms
News & Updates
Cytovale has secured $84 million in Series C funding to accelerate the commercialization of its innovative sepsis diagnostic technology.
A peer-reviewed study confirms that Cytovale’s rapid diagnostic reduces sepsis mortality by 39%.
Rhonda Collins has been appointed as Chief Nursing Officer at Cytovale.
Dave Vort has been appointed as Chief Commercial Officer at Cytovale.
Cytovale’s IntelliSep test received FDA 510(k) clearance for early sepsis detection.
Latest study shows Cytovale’s sepsis diagnostic test has a negative predictive value of 97.5%.
Cytovale has secured $84 million in Series C funding to accelerate the commercialization of its innovative sepsis diagnostic technology.
A peer-reviewed study confirms that Cytovale’s rapid diagnostic reduces sepsis mortality by 39%.
Rhonda Collins has been appointed as Chief Nursing Officer at Cytovale.
Dave Vort has been appointed as Chief Commercial Officer at Cytovale.
Cytovale’s IntelliSep test received FDA 510(k) clearance for early sepsis detection.
Latest study shows Cytovale’s sepsis diagnostic test has a negative predictive value of 97.5%.